Hypera S.A. (BOVESPA: HYPE3)
Health Care · Pharmaceuticals · BR
R$26.93
+0.86% today · +29.0% 1Y
Hypera S.A. (BOVESPA: HYPE3) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.81B and employs 10,564 people.
Over the last twelve months the share price has gained 29.0%, trading between 19.88 and 30.00.
Tweenvest scores Hypera S.A. across four factors: quality 69/100, value 66/100, growth 22/100, dividend 100/100. Its strongest factor is dividend.
HYPE3 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.81B
- Revenue (TTM)
- $1.70B
- P/E
- 10.15
- EPS
- 2.66
- Dividend yield
- 4.38%
- Beta (5Y)
- 0.07
- 52-week high
- R$30.00
- 52-week low
- R$19.88
- Avg volume (3M)
- —
- Shares outstanding
- 703.99M
- Employees
- 10,564
- Next earnings
- —
About Hypera S.A.
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
- ISIN
- BRHYPEACNOR0
- Founded
- 1999
- Listed since
- Apr 18, 2008
- Exchange
- Bolsa de Valores de Sao Paulo
- Currency
- BRL
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| J. B. Chemicals & Pharmaceuticals LimitedBSE: 506943 | $4.02B | Rs— | — |
| Zhejiang Huahai Pharmaceutical Co., Ltd.SHSE: 600521 | $3.88B | CN¥17.45 | +6.79% |
| Shijiazhuang Yiling Pharmaceutical Co., Ltd.SZSE: 002603 | $3.87B | CN¥15.53 | +1.17% |
| Camurus AB (publ)OM: CAMX | $3.81B | Skr639.50 | -0.23% |
| Caliway Biopharmaceuticals Co., Ltd.TWSE: 6919 | $3.77B | NT$77.50 | -3.00% |
| Hubei Jumpcan Pharmaceutical Co., Ltd.SHSE: 600566 | $3.67B | CN¥26.70 | +2.61% |
| Regencell Bioscience Holdings LimitedNasdaqCM: RGC | $3.64B | $7.12 | -3.13% |
| Organon & Co.NYSE: OGN | $3.63B | $13.80 | -0.11% |
Figures last refreshed Oct 11, 2026.